Data supplements
Appendix 1: Approval times for new drugs, by TPP division
Division/country No. of new drugs approved Approval time (in calendar days)
Median Mean Range
AIDS and Viral Diseases Canada 8 546 486 185–815 Australia 12 266 305 141–628 Sweden 12 368 349 153–508 United Kingdom 8 264 307 182–490 United States 11 139 165 42–344 Bureau of Biologics and Radiopharmaceuticals Canada 19 698 808 108–2454 Australia 17 533 576 364–964 Sweden 16 463 467 113–698 United Kingdom 5 567 490 174–679 United States 23 459 546 147–2971 Central Nervous System Canada 19 428 469 273–744 Australia 19 528 553 314–769 Sweden 24 357 315 88–615 United Kingdom 15 245 331 88–1119 United States 22 515 534 241–1087 Cardiovascular Canada 9 547 574 240–963 Australia 11 538 569 378–1051 Sweden 20 336 348 122–892 United Kingdom 9 308 329 107–642 United States 14 384 592 183–3053 Endocrine, Metabolism and Arthritis Canada 13 539 570 253–1017 Australia 13 555 571 314–1130 Sweden 14 332 351 112–763 United Kingdom 9 313 384 137–1078 United States 22 362 402 167–928 Gastrointestinal, Hematology and Oncology Canada 21 549 582 277–1048 Australia 14 553 570 379–953 Sweden 12 392 346 122–574 United Kingdom 5 330 346 80–678 United States 18 387 506 159–1619 Infection and Immunology Canada 8 574 754 408–1937 Australia 8 611 621 383–840 Sweden 9 275 362 107–700 United Kingdom 4 139 228 107–525 United States 13 365 666 182–1926
Note: TPP = Therapeutic Products Program, Health Canada.
In this issue
Article tools
Respond to this article
Jump to section
Related Articles
Cited By...
- Regulatory approval time for hormonal contraception in Canada, the United States and the United Kingdom, 2000-2015: a retrospective data analysis
- Emergent Patterns in the Regulation of Pharmaceuticals: Institutions andInterests in the United States, Canada, Britain, and France
- Drug approval times
- PubMed Central: signing on
More in this TOC Section
Similar Articles
Collections
